IDE849 (SHR-4849): a potential first-in-class Phase 1 DLL3 TOP1i antibody drug conjugate (ADC ... IDE892: a potential best-in-class MTA-cooperative PRMT5 inhibitor to enable wholly-owned ...

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

. Introduction: By depleting autoreactive B cells, CD19-targeted CAR-T have shown early yet promising efficacy in treating patients with B cell-driven autoimmune diseases. However, the clinical ...

in combination with Gilead’s Trodelvy (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion urothelial cancer based on ...

The cuts are "in light of the extremely challenging financial markets" and the biotech's "strong conviction in the value of our clinical programs," which include two PRMT5 inhibitor cancer candidates.

For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024. Product sales grew 11%, primarily driven by 14% ...

NEW YORK – Ideaya Biosciences said last week that it has begun a Phase I/II trial expansion of its MAT2A inhibitor IDE397 in combination with Gilead's Trop-2 directed antibody-drug conjugate ... of ...